DBV Technologies Locks in $306M to Rocket Viaskin Peanut Patch to U.S. Shores
DENVER, Colo., Mar 28, 2025 (247marketnews.com)- DBV Technologies (NASDAQ:DBVT) just closed a blockbuster financing deal worth up to $306.9 million (€284.5 million) to turbocharge its Viaskin Peanut Patch. The haul includes $125.5 million (€116.3 million) upfront and up to $181.4 million (€168.2 million) more if warrants fully cash out, fueling the patch’s sprint through a Biologics License Application (BLA) to the FDA and a potential U.S. launch for kids aged 4-7, pending approval.
The funding consists of a mix of 34 million new shares at €1.1136 each with ABSA warrants and 71 million pre-funded warrant units, unlocking up to 254.9 million total shares if fully exercised.
Daniel Tassé, DBVT’s CEO, commented, “DBV is developing the Viaskin peanut patch for the treatment of pediatric peanut allergy. This injection of capital is coming on the heels of news issued earlier this week announcing alignment with the FDA on safety exposure data required for a BLA for Viaskin peanut patch in 4 – 7-year-olds, accelerating the timeline for a BLA filing submission upon potential successful completion of VITESSE. I wish to again thank the FDA for their engagement and quick response. We are thrilled that this significant transaction will support our transition to a commercial organization as we progress towards completing the required studies and start preparing the dossiers for FDA review and launch, if approved, for both Viaskin peanut patch indications in toddlers 1 – 3 and children 4 – 7 years-old.”
DBV’s patch, which zaps microdoses of peanut protein through skin to tame allergic reactions may become a lifeline for over 1 million U.S. kids.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com